Russian drugmaker, Pharmstandard, has posted a FY 2008 Net Profit of 3.5 billion Roubles under IFRS.

The bottom line was up 7% on the FY 2007 Net Profit with EBITDA rising 24% to 6.04 billion Roubles on Revenues of 14.47 billion Roubles, up 26%.

The company attributed the result to a promotional campaign on a range of products including anti viral drug Arbidol, and increase synergies stemming from the decision to transfer production of key drugs including Arbidol and Flukostat to Pharmstandard’s own production facilities.